| abstract |
The invention discloses a nanobody recombinant protein for treating rheumatoid arthritis, belonging to the field of genetic engineering. Linker peptides are fused together to form a fusion antibody, the amino acid sequence of which is set forth in SEQ ID No. 1 or includes at least 80%, 85%, 90%, 95%, 98% or 99% identity to SEQ ID No. 1 The present invention provides an anti-TNF-α nanobody recombinant protein, which can be used for the prevention or treatment of rheumatoid arthritis, and has the advantages of safety, reliability and strong specificity. |